• Altered drug targets: Cancer cells may acquire genetic alterations that modify the targets of chemotherapy treatments, rendering them ineffective—for instance, mutations in drug target genes like the epidermal growth factor receptor (EGFR) in lung cancer, leading to resistance to EGFR inhibitors (49, 50). This evidence concerns the gene EGFR and lung cancer.